Peptides for Oral Mucositis After Chemo
Peptide Therapies for Chemotherapy Side Effects
98% incidence
Oral mucositis affects up to 98% of patients undergoing stem cell transplant for blood cancers. Palifermin, a growth factor peptide, is the only FDA-approved treatment.
Spielberger et al., NEJM, 2004
Spielberger et al., NEJM, 2004
View as imageOral mucositis is among the most painful and debilitating side effects of cancer treatment. Chemotherapy and head-and-neck radiation destroy the rapidly dividing epithelial cells that line the mouth, producing ulcers that can prevent eating, drinking, and speaking. In patients undergoing stem cell transplant with high-dose chemotherapy, mucositis develops in up to 98% of cases. In head-and-neck cancer patients receiving chemoradiation, severe mucositis (grade 3-4) occurs in 50-80% of patients and frequently forces treatment interruptions that compromise cancer outcomes. Despite this burden, only one drug has been approved specifically for oral mucositis. It is a peptide. For a broader view of how peptides address chemotherapy side effects, see our pillar article on peptide therapies for chemotherapy side effects.
Key Takeaways
- Palifermin (keratinocyte growth factor-1), the only FDA-approved treatment for oral mucositis, reduced grade 3/4 mucositis from 98% to 63% in stem cell transplant patients in a pivotal NEJM trial (Spielberger et al., 2004)
- Dusquetide, a 5-amino-acid innate defense regulator peptide, reduced severe oral mucositis duration by 56% (18 to 8 days) in a Phase 3 trial of 266 head-and-neck cancer patients, but missed statistical significance in the intent-to-treat analysis
- Antimicrobial peptides serve dual roles in oral mucositis: defending against secondary infections and directly promoting epithelial wound healing through growth factor signaling (Mangoni et al., Experimental Dermatology, 2016)
- LL-37, the human cathelicidin, promoted wound healing through re-epithelialization, angiogenesis, and inflammatory modulation in preclinical wound models (Carretero et al., Journal of Investigative Dermatology, 2008)
- BPC-157 demonstrated mucosal cytoprotection through interactions with adrenergic and dopaminergic systems in stress-induced mucosal damage models (Sikiric et al., Digestive Diseases and Sciences, 1997)
- Antimicrobial peptides have emerging potential to treat oral infections and potentially oral cancers, expanding the therapeutic landscape beyond mucositis alone (Carvalho et al., Frontiers in Medicine, 2025)
Why Cancer Treatment Destroys the Oral Mucosa
The oral epithelium renews itself every 7-14 days, making it one of the fastest-dividing tissues in the body. Chemotherapy agents and radiation target rapidly proliferating cells. They cannot distinguish between cancer cells and the basal epithelial cells that continuously regenerate the oral lining.
The injury unfolds in five overlapping phases. First, chemotherapy or radiation generates reactive oxygen species that damage DNA in basal epithelial cells. Second, transcription factors (NF-kB, p53) activate, triggering apoptosis and inflammatory cytokine release (TNF-alpha, IL-1beta, IL-6). Third, these signals amplify the damage through positive feedback loops that recruit neutrophils and macrophages. Fourth, the epithelium breaks down completely, producing painful ulcers that expose the underlying submucosa to oral bacteria. Fifth, secondary infection by oral flora, including Gram-negative bacteria and fungi, worsens the ulceration and delays healing.
This five-phase model, developed by Sonis and colleagues, explains why simple anti-inflammatory or antimicrobial interventions have limited effect: the damage involves DNA injury, inflammatory amplification, barrier breakdown, and infection simultaneously. Peptide therapies can potentially address multiple phases: growth factors accelerate epithelial regeneration (phase 5), innate defense regulators modulate the inflammatory cascade (phases 2-3), and antimicrobial peptides control secondary infection (phase 4).
Palifermin: The Only Approved Peptide
Palifermin (Kepivance) is a recombinant form of keratinocyte growth factor-1 (KGF-1), a 140-amino-acid protein that stimulates proliferation, differentiation, and migration of epithelial cells. It binds the FGFR2b receptor expressed specifically on epithelial cells, including those lining the oral cavity.
The pivotal trial, published in the New England Journal of Medicine in 2004, randomized patients undergoing autologous stem cell transplant for hematological malignancies. Palifermin was administered intravenously at 60 micrograms/kg/day for three days before conditioning therapy and three days after transplant. The results were definitive: 63% of palifermin-treated patients developed grade 3 or 4 mucositis, compared to 98% in the placebo group. Among those who developed mucositis, the median duration was 6 days shorter with palifermin. Patients on palifermin used fewer opioid analgesics and required less total parenteral nutrition.
FDA approval followed in 2004, but with a narrow indication: severe oral mucositis in patients with hematological malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. This limitation exists because the evidence base in solid tumor patients receiving standard chemotherapy or head-and-neck radiation was less compelling. Several trials in head-and-neck cancer showed trends toward benefit but did not consistently reach statistical significance.
Palifermin's mechanism raises a theoretical concern. KGF-1 stimulates epithelial proliferation, and some cancers express FGFR2b. Could palifermin promote tumor growth? The clinical trial data have not confirmed this risk, and palifermin is administered at doses that produce transient, localized epithelial effects. However, this concern has limited enthusiasm for broader use outside the stem cell transplant setting.
Dusquetide: An Innate Defense Regulator
Dusquetide (SGX942) represents a different class of peptide therapeutic. It is a five-amino-acid synthetic peptide classified as an innate defense regulator (IDR). Rather than directly stimulating epithelial growth, dusquetide modulates the innate immune response to injury and infection by selectively binding to the ZZ domain of sequestosome-1 (SQSTM1/p62), a scaffold protein involved in inflammatory signaling and autophagy.
The Phase 3 DOM-INNATE trial enrolled 266 patients with head-and-neck cancer receiving concurrent chemoradiation. Dusquetide reduced the median duration of severe oral mucositis (SOM) from 18 days in the placebo arm to 8 days in the treatment arm, a 56% reduction. However, the difference did not reach statistical significance in the intent-to-treat (ITT) population. In the per-protocol population, a statistically significant 50% reduction was observed (18 to 9 days).
The failure to reach significance in the ITT analysis does not necessarily mean the drug is ineffective. The ITT population includes patients who dropped out or had protocol deviations, diluting the treatment effect. The per-protocol result, which includes only patients who completed the study as designed, was positive. Regulatory agencies typically weight the ITT result more heavily, and the Phase 3 failure has slowed dusquetide's path to approval.
Dusquetide's mechanism is mechanistically distinct from palifermin. It addresses the inflammatory amplification phase (phases 2-3) rather than the epithelial regeneration phase (phase 5). In theory, combining an IDR peptide with a growth factor like palifermin could address multiple phases of mucositis simultaneously. No combination trial has been conducted.
Iseganan: The Antimicrobial Peptide That Failed
Iseganan (IB-367) is a synthetic analog of protegrin-1, an antimicrobial peptide from porcine leukocytes. It was developed as a topical oral rinse to prevent mucositis by controlling the bacterial colonization that worsens ulceration. The rationale was sound: oral mucositis ulcers are colonized by pathogenic bacteria that drive inflammatory signaling and delay healing.
A Phase 3 randomized controlled trial tested iseganan oral rinse in patients receiving cancer therapy. The trial failed. Iseganan did not reduce the incidence or severity of oral mucositis compared to placebo. The failure likely reflected a fundamental limitation of the antimicrobial-only approach: by the time bacteria colonize mucositis ulcers, the epithelial damage is already established through direct cytotoxic effects. Killing bacteria cannot reverse the underlying tissue destruction.
This failure helped establish an important principle in mucositis research: infection control alone is insufficient. Effective peptide therapies need to address the epithelial damage directly, not just its bacterial consequences.
LL-37 and the Dual Role of Antimicrobial Peptides
Despite iseganan's failure, the antimicrobial peptide field has evolved to recognize that many AMPs do far more than kill bacteria. LL-37, the only human cathelicidin, exemplifies this dual functionality. Carretero and colleagues demonstrated that LL-37 promoted wound healing through multiple mechanisms: enhanced re-epithelialization, angiogenesis stimulation, and modulation of the inflammatory response. In both in vitro keratinocyte models and in vivo wound models, LL-37 accelerated closure and improved tissue quality.[1]
Ramos and colleagues confirmed these findings, showing that LL-37's wound healing activity was independent of its antimicrobial function. The peptide activated formyl peptide receptor-like 1 (FPRL1) on epithelial cells, triggering proliferation and migration signals. This receptor-mediated pathway explains why LL-37 promotes healing even in sterile wound environments where its antimicrobial activity is irrelevant.[2]
A 2016 review in Experimental Dermatology synthesized the evidence, concluding that antimicrobial peptides serve dual roles as both defenders against microbial infections and endogenous mediators of wound healing. The authors argued that this dual functionality makes them particularly promising for epithelial injuries where both infection control and tissue repair are needed, a description that precisely matches oral mucositis.[3]
LL-37 has not been tested clinically for oral mucositis. The gap between its wound healing potential and clinical application reflects practical challenges: peptide stability in the oral environment (saliva contains proteases), delivery to ulcerated surfaces, and the need for sustained exposure during the healing period.
BPC-157: Mucosal Cytoprotection in Animal Models
BPC-157, a 15-amino-acid peptide derived from human gastric juice, has been studied for mucosal protection in several animal models relevant to oral mucositis. Sikiric and colleagues demonstrated that BPC-157 interacts with adrenergic and dopaminergic neurotransmitter systems to produce mucosal protection during stress. The peptide attenuated stress-induced mucosal lesions through mechanisms that go beyond simple epithelial effects, suggesting central nervous system involvement in its cytoprotective activity.[4]
Later work from the same group explored BPC-157's cytoprotective concept through intraoral and intragastric administration, demonstrating that the peptide could protect mucosal surfaces when applied directly to the oral cavity. The concept of "adaptive cytoprotection," where prior peptide exposure primes mucosal defenses against subsequent injury, is relevant to mucositis prevention in cancer patients who could potentially receive BPC-157 before chemotherapy.[5]
The BPC-157 mucositis evidence has substantial limitations. All studies come from a single research group. No study has specifically tested BPC-157 in a chemotherapy or radiation mucositis model. The animal models used (stress-induced mucosal lesions) are mechanistically different from cancer therapy-induced mucositis, which involves direct DNA damage to basal epithelial cells. For more on BPC-157's mucosal effects, see how BPC-157 may protect the gut lining.
Antimicrobial Peptides Beyond Mucositis
A 2025 review in Frontiers in Medicine examined the broader potential of antimicrobial peptides to treat oral infections and oral cancers. While not specific to mucositis, the review highlights the expanding therapeutic landscape for peptides in the oral cavity. Antimicrobial peptides can target oral pathogens including Streptococcus mutans, Porphyromonas gingivalis, and Candida species, all of which colonize mucositis ulcers and worsen outcomes.[6]
The therapeutic utility of antibacterial peptides in wound healing was reviewed by Otvos and colleagues, who argued that peptides with combined antimicrobial and wound-healing properties represent the most rational approach to infected wounds, a category that includes mucositis ulcers.[7]
These reviews point toward a next-generation approach: engineered peptides that combine antimicrobial activity with direct wound healing promotion, addressing multiple phases of mucositis simultaneously. No such combination peptide has reached clinical trials for oral mucositis. For related reading on the ghrelin agonists being studied for cancer cachexia, another major chemotherapy side effect, see our companion article.
Trefoil Factor Peptides: Endogenous Mucosal Protectors
Trefoil factor peptides (TFF1, TFF2, TFF3) are small proteins secreted by goblet cells throughout the gastrointestinal tract, including the oral mucosa. They play essential roles in mucosal maintenance: promoting epithelial restitution (rapid migration of cells to cover wounds), stimulating mucus secretion, and inhibiting apoptosis in mucosal epithelial cells.
In animal models of gastrointestinal mucositis, trefoil factor expression is upregulated after injury, consistent with an endogenous protective response. Exogenous administration of trefoil peptides has accelerated mucosal healing in radiation-induced intestinal damage models. The oral mucosa expresses trefoil factors, and their depletion during chemotherapy may contribute to mucositis severity.
No clinical trial has tested trefoil factor peptides specifically for oral mucositis. The concept remains preclinical, but the rationale is strong: replacing or supplementing the endogenous mucosal protectors that are depleted by cancer therapy could provide physiological mucosal defense during the vulnerable treatment period.
Where Peptide Mucositis Therapies Stand
The peptide landscape for oral mucositis is defined by a single success, a near-miss, and a failure. Palifermin works but is limited to stem cell transplant patients. Dusquetide showed biological activity but did not reach statistical significance in the ITT analysis of its Phase 3 trial. Iseganan failed entirely because antimicrobial activity alone does not address the underlying epithelial damage.
The lesson across these three programs is consistent with the five-phase model of mucositis: effective therapy requires addressing the epithelial destruction directly, not just its consequences. Growth factors (palifermin) and immune modulators (dusquetide) have shown the most promise because they target the injury and inflammatory phases rather than the secondary infection phase that iseganan addressed.
The preclinical pipeline offers hints of more sophisticated approaches. LL-37's dual antimicrobial and wound-healing activity, BPC-157's mucosal cytoprotection, and trefoil factors' endogenous protective function all suggest that peptides targeting multiple phases simultaneously could outperform single-mechanism drugs. But none of these candidates has been tested in a mucositis-specific clinical trial. The gap between preclinical wound healing data and clinical mucositis evidence remains wide.
The Bottom Line
Palifermin remains the only FDA-approved peptide for oral mucositis, reducing severe cases from 98% to 63% in stem cell transplant patients. Dusquetide showed a 56% reduction in severe mucositis duration but failed to reach statistical significance in Phase 3. Iseganan's failure demonstrated that antimicrobial activity alone is insufficient. LL-37, BPC-157, and trefoil factor peptides show preclinical promise through combined antimicrobial and wound-healing mechanisms, but none has been tested in clinical mucositis trials. The field needs peptides that address multiple injury phases simultaneously.